These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31630053)

  • 1. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
    Haider K; Pathak A; Rohilla A; Haider MR; Ahmad K; Yar MS
    Eur J Med Chem; 2019 Dec; 184():111773. PubMed ID: 31630053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors.
    Zhao X; Sun B; Zheng H; Liu J; Qian L; Wang X; Lou H
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2201-2205. PubMed ID: 29764742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
    Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy.
    Mohan V; Mithal A; Joshi SR; Aravind SR; Chowdhury S
    Drug Des Devel Ther; 2020; 14():2487-2501. PubMed ID: 32612352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition.
    Ng WL; Li HC; Lau KM; Chan AKN; Lau CB; Shing TKM
    Sci Rep; 2017 Jul; 7(1):5581. PubMed ID: 28717146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes.
    Pan X; Huan Y; Shen Z; Liu Z
    Eur J Med Chem; 2016 May; 114():89-100. PubMed ID: 26974378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
    Wan HX; Shen JK
    Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Lee SH; Song KS; Kim JY; Kang M; Lee JS; Cho SH; Park HJ; Kim J; Lee J
    Bioorg Med Chem; 2011 Oct; 19(19):5813-32. PubMed ID: 21906953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors.
    Chu KF; Song JS; Chen CT; Yeh TK; Hsieh TC; Huang CY; Wang MH; Wu SH; Yao CH; Chao YS; Lee JC
    Bioorg Chem; 2019 Mar; 83():520-525. PubMed ID: 30469144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
    J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners.
    Lee J; Lee SH; Seo HJ; Son EJ; Lee SH; Jung ME; Lee M; Han HK; Kim J; Kang J; Lee J
    Bioorg Med Chem; 2010 Mar; 18(6):2178-2194. PubMed ID: 20181486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
    Kumar S; Khatik GL; Mittal A
    Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
    Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review.
    Manoj A; Das S; Kunnath Ramachandran A; Alex AT; Joseph A
    Future Med Chem; 2020 Nov; 12(21):1961-1990. PubMed ID: 33124462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
    Cai W; Jiang L; Xie Y; Liu Y; Liu W; Zhao G
    Med Chem; 2015; 11(4):317-28. PubMed ID: 25557661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
    Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.